Diabetic Dyslipidemia: Current Concepts in Pathophysiology and Management
| Autor: | Ankita Aggarwal, Debasish Chaudhury |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
medicine.medical_specialty
adiponectin business.industry lcsh:R Clinical Biochemistry nutritional and metabolic diseases lcsh:Medicine 030209 endocrinology & metabolism General Medicine 030204 cardiovascular system & hematology Pathophysiology statins lipoproteins Diabetic dyslipidemia 03 medical and health sciences 0302 clinical medicine atherogenic dyslipidemia Medicine Current (fluid) business Intensive care medicine |
| Zdroj: | Journal of Clinical and Diagnostic Research, Vol 12, Iss 1, Pp OE06-OE09 (2018) |
| ISSN: | 2249-782X |
| Popis: | Diabetes Mellitus (DM) has assumed pandemic proportions worldwide. The increase in prevalence of this non-communicable disease has been quite alarming. South East Asia is home to approximately 71.4 million of the diabetics, out of which 61.3 million diabetics are in India in 2011 as per the data of International Diabetic Federation. The leading causes of morbidity and mortality for such patients have been attributed to the rising incidences of Cardiovascular Diseases (CVD) as a complication of type 2 diabetes. A major proportion of CVDs are attributed to the occurrence of atherogenic dyslipidemia. The pathophysiologic mechanisms and treatment regimens for dyslipidemia have been evolving and several newer mechanisms are being proposed. The purpose of the review is to throw light on the new concepts regarding pathophysiology and management guidelines of diabetic dyslipidemia. A literature review was performed in pubMed and google using the key words: type 2 DM, dyslipidemia, pathophysiology, treatment. A total of 30 articles over last 10 years were scanned for review. The newer mechanisms of dyslipidemia included: activation of transcription factors, decreased Lipoprotein Lipase (LPL), decreased clearance. The role of remnant particles, adiponectin an antiinflammatory molecule has also been proposed. The current treatment regimens are based on Low Density Lipoproteins (LDL) and high density lipoproteins (HDL) and the recommendations are different for the various associations. Statins are considered the standard lipid lowering agents in diabetics and have shown mortality benefits in these patients. However, many new drugs like Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors, saroglitazar are emerging as possible alternates for statins in the treatment of dyslipidemia, though their overall cardiovascular benefit is yet to be studied. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|